You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
受Alexion藥品和疫苗訂單銷售額提振 阿斯利康(AZN.US)首季營收同比增55%
格隆匯 04-29 15:18

格隆匯4月29日丨阿斯利康(AZN.US)週五表示,截至至3月的一季度,營收達113.9億美元,同比增55.6%,這主要得益於被收購的公司Alexion的藥品和今年將交付的新冠病毒疫苗訂單的貢獻。本季淨利達3.86億美元,低於上年同期的15.6億美元,同比減少75.26%;本季度核心每股收益升至1.89美元,較上年同期增長16%。EBITDA收益受到11.8億美元公允價值提升的負面影響,為21.9億美元,同比減18.59%。展望未來,阿斯利康表示,預計2022年總收入將增長10%至10%,而核心每股收益預計將增長至20%中高位數。但公司表示,考慮到新冠藥品的銷售下降,預計這些藥品的毛利率將低於公司平均水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account